Pancreatic Cancer
Conditions
Keywords
SPARC (secreted protein acid rich in cysteine), serum Carbohydrate Antigen CA 19-9
Brief summary
LE-DT is a novel, proprietary delivery system of docetaxel developed by NeoPharm, Inc. Docetaxel (currently marketed as Taxotere) is an anti-microtubule agent that prevents cell division. By removing toxic detergent used in Taxotere, the form of LE-DT, shows reduced toxicity and comparable therapeutic efficacy in pre-clinical study. The clinical evidence obtained from the NeoPharm Phase I study shows fewer side effects and possibly administered at higher dose to induce greater effectiveness of LE-DT. In addition, docetaxel has shown positive activity of protein bound taxane therapy in treating patients with pancreatic cancer. The current Phase II study is designed to accomplish the following objectives: 1. Assess the antitumor effect of 110 mg/m2 LE-DT administered intravenous (IV) every three weeks in pancreatic cancer patients with locally advanced or metastatic disease 2. To evaluate the progression-free survival and overall survival 3. To correlate secreted protein acid rich in cysteine expression with tumor response 4. To evaluate the safety of LE-DT, in particular peripheral neuropathy, water retention as well as myelotoxicity 5. To correlate pharmacogenetic variations in patients with LE-DT pharmacodynamic endpoints, including toxicities.
Interventions
110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
Sponsors
INSYS Therapeutics Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient is 18 years or older, male and female. 2. Patient has histopathologically confirmed diagnosis of adenocarcinoma of the pancreas. Patients with islet cell neoplasms are excluded. Biopsy sample must be available for SPARC assay. 3. Patients must have clinical or radiographic evidence of locally advanced or metastatic pancreatic cancer with measurable disease. 4. Male or non-pregnant and non-lactating female: * If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test (β hCG) documented within 72 hours of the first administration of study drug. * If sexually active, the patient must agree to use contraception considered adequate and appropriate by the Investigator. 5. Patient can be newly-diagnosed without prior treatment or have failed initial adjuvant treatment with either gemcitabine, 5-FU or capecitabine with or without radiation therapy. 6. Patient has the following blood counts at baseline: * ANC greater than or equal to 1500 per uL * Platelets greater than or equal to 100000 per uL * Hgb greater than or equal to 9 g per dL 7. Patient has the following blood chemistry levels at baseline: * AST (SGOT), ALT (SGPT) less than or equal to 2.5 times of the upper limit of normal range (ULN), unless liver metastases are present, then less than or equal 5 times of the ULN is allowed * Bilirubin less than or equal to 1.5 times of the ULN * Serum creatinine less than or equal to 1.5 times of the ULN or calculated clearance greater than or equal to 60 mL/min for patients with serum creatinine levels above the institutional normal value. 8. Patient has acceptable coagulation profile as indicated by a Prothrombin time (PT) and Partial Thromboplastin Time (PTT) within normal limits (plus or minus 15%) unless explained by the use of anticoagulants 9. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-2 10. Patient has one or more metastatic lesions or locally advanced primary tumor measurable by CT or MRI. 11. Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board-approved written informed consent form prior to receiving any study related procedure.
Exclusion criteria
1. Patient has known brain metastases. 2. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. 3. Patient has known infection with HIV, hepatitis B, or hepatitis C. 4. Patient has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study. 5. Patient who have received any other treatment for pancreatic cancer including radiotherapy, chemotherapy or any investigational therapy with the exception of initial adjuvant treatment including either gemcitabine, 5-FU or capecitabine with or without radiation therapy 6. Patient has a history of allergy or hypersensitivity to the study drug. 7. Patient has serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the patient to receive an experimental research drug. 8. Patient has pre-existing peripheral neuropathy of Grade \>1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 9. Patient is unwilling or unable to comply with study procedures. 10. Patient is enrolled in any other clinical or investigational trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response rate of tumor size reduction at 110 mg/m2 LE-DT dose level | 1 year | Measurable disease response will be assessed by radiographic method, CT or MRI, along with serum CA 19-9 after completed 2, 4 and 6 cycle. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SPARC tumor expression following the treatment of LE-DT at 110 mg/m2 dose level | 1 year | SPARC tumor expression will be assessed as a potential predictor of tumor response |
Countries
United States
Outcome results
None listed